shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin
ConclusionIn this experimental model, combined therapy with chemotherapy and Adv-shPGK1 improves control of PM of gastric origin as compared to chemotherapy alone and might counteract chemoresistance of PM. A systemic toxicity of Adv-shPGK1 cannot be excluded.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Orthopaedics | Statistics | Surgery | Toxicology